Business
Curis Provides Updated Data from its Frontline AML Triplet Study
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).
About this update from Curis, Inc.
[{"type":"text","content":"5 of 8 patients (62.5%) achieved Undetectable MRD (uMRD)","length":56,"tagName":"p","attribs":{}},{"type":"text","content":"LEXINGTON, Mass., Dec. 9, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, yesterday provided updated clinical data from the ongoing frontline Acute Myeloid Leukemia (AML) triplet study (CA-4948-104) in a poster presentation at the 67th ASH Annual Meeting (ASH).","length":401,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Curis, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Curis, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":207,"url":"https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bs_Ynz1IdxzlIjT8sYZeig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM2NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/88fd3af4c52bfd02eedb20e78872ec1a","width":400,"height":207}},"href":"https://mma.prnewswire.com/media/607886/Curis_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The AML triplet study is evaluating the addition of emavusertib (ema) to the combination of venetoclax and azacitidine (ven-aza) in AML patients who have achieved complete remission on ven-aza but remain MRD-positive (MRD+), with the goal of enabling patients to achieve uMRD. The first two cohorts in the study evaluate patients who received emavusertib for either 7 or 14 days in a 28-day cycle, in addition to their ven-aza treatment regimen.","length":445,"tagName":"p"},{"type":"text","content":"In the ASH abstract, the company reported initial data showing 4 of 8 patients (50%) had achieved uMRD as of July 2, 2025. These data were updated in the poster presented at ASH with 5 of 8 patients (62.5%) achieving uMRD, with no change in safety profile, as of October 12, 2025.","length":285,"tagName":"p"},{"type":"text","content":""These data are very promising and warrant further evaluation of additional triplet (ema/ven/aza) regimens to determine the optimal dose and schedule for safety and efficacy to improve patient outcomes in a difficult to treat population," said James Dentzer, Curis's Chief Executive Officer.","length":305,"tag...